Last quarter (Q ), Arch Therapeutics's total revenue was $45.87K, an increase of 2828.93% from the same quarter last year. In Q, Arch Therapeutics's net income was $-2.68M. See Arch Therapeutics’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Sep 22	Sep 21	Sep 20	Sep 19	Sep 18
Total Revenue	$ 82.08K	$ 15.65K	$ 11.56K	$ 0.00	$ 0.00	$ 0.00
Cost of Revenue	$ -1.08K	$ 51.49K	$ 26.28K	$ 0.00	-	-
Gross Profit	$ 83.16K	$ -35.84K	$ -14.72K	$ 0.00	-	-
Operating Expense	$ 2.37M	$ 5.67M	$ 6.36M	$ 5.35M	$ 6.37M	$ 7.45M
Operating Income	$ -2.31M	$ -5.71M	$ -6.38M	$ -5.35M	$ -6.37M	$ -7.45M
Net Non Operating Interest Income Expense	$ -3.18M	$ -567.05K	$ -150.53K	$ -18.53K	-	$ 0.00
Other Income Expense	$ -1.14M	$ -1.00M	$ -287.17K	$ 679.27K	$ 1.82M	$ 2.64M
Pretax Income	$ -4.32M	$ -5.28M	$ -6.24M	$ -4.69M	$ -4.55M	$ -4.81M
Tax Provision	-	-	-	-	-	-
Earnings From Equity Interest Net Of Tax	-	-	-	-	-	-
Net Income Common Stockholders	$ -4.32M	$ -5.28M	$ -6.24M	$ -4.69M	$ -4.55M	$ -4.81M
Basic EPS	$ -4.14	$ -0.02	$ -6.00	$ -0.02	$ -0.03	$ -0.03
Diluted EPS	$ -4.14	$ -0.02	$ -6.00	$ -0.02	$ -0.03	$ -0.03
Basic Average Shares	$ 8.50M	$ 239.91M	$ 1.10M	$ 188.05M	$ 166.34M	$ 152.71M
Diluted Average Shares	$ 8.50M	$ 239.91M	$ 1.10M	$ 188.05M	$ 166.34M	$ 152.71M
Dividend Per Share	-	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-	-
Rent Expense Supplemental	-	-	-	-	-	-
Total Expenses	$ -198.11K	$ -5.72M	$ 6.39M	$ 5.35M	$ 6.37M	$ 7.45M
Net Income From Continuing And Discontinued Operation	$ -7.21M	$ -5.28M	$ -6.24M	$ -4.69M	$ -4.55M	$ -4.81M
Normalized Income	$ -4.08M	$ -4.17M	-	$ -5.37M	$ -6.37M	$ -7.45M
Interest Expense	-	-	-	$ 18.53K	-	$ 0.00
EBIT	$ -1.14M	$ -4.71M	$ -6.09M	$ -4.67M	$ -6.37M	$ -7.45M
EBITDA	$ -1.14M	$ -4.71M	$ -6.09M	$ -4.67M	$ -6.36M	$ -7.44M

Currency in USD

Arch Therapeutics Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing